Evoke Pharma (NASDAQ: EVOK)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-11 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.480 | -0.840 | -0.3600 | ||||
REV | 530.000K | 418.380K | -111.620K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Evoke Pharma (NASDAQ: EVOK) through any online brokerage.
Other companies in Evoke Pharma’s space includes: Cingulate (NASDAQ:CING), Dermata Therapeutics (NASDAQ:DRMA), Pulmatrix (NASDAQ:PULM), Baudax Bio (NASDAQ:BXRX) and Titan Pharmaceuticals (NASDAQ:TTNP).
The latest price target for Evoke Pharma (NASDAQ: EVOK) was reported by HC Wainwright & Co. on Monday, June 22, 2020. The analyst firm set a price target for 10.00 expecting EVOK to rise to within 12 months (a possible 214.47% upside). 0 analyst firms have reported ratings in the last year.
The stock price for Evoke Pharma (NASDAQ: EVOK) is $3.18 last updated June 29, 2022, 8:00 PM UTC.
There are no upcoming dividends for Evoke Pharma.
Evoke Pharma’s Q2 earnings are confirmed for Thursday, August 11, 2022.
There is no upcoming split for Evoke Pharma.
Evoke Pharma is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.